GEN Exclusives

More »

Feature Articles

More »
Nov 1, 2011 (Vol. 31, No. 19)

Redefining High-Resolution Mass Spec

FAIMS and Other Advances Greatly Extend Technological Boundaries

  • Click Image To Enlarge +
    Researchers at the Pacific Northwest National Lab have achieved the highest resolution to date with planar FAIMS. A custom planar FAIMS unit is shown secured to the front end of a mass spectrometer.

    Tradeoffs between resolution, sensitivity, and speed are inevitable in chemical analysis but strides are being taken to boost resolution and to improve “qual-quant” methods that enable researchers to identify and quantify compounds in a single workflow.

    Chromatography and mass spec (MS) are the staples in these efforts, but newer assistive technologies such as FAIMS and improved software are also extending the reach of these traditional tools. This was made vividly clear during a number of presentations at “Pittcon”, held in Atlanta earlier this year.

    FAIMS (high-field asymmetric waveform ion mobility spectrometry) is already demonstrating higher resolution for peptides and lipids and shows great promise for applications identifying post-translational modifications (PTMs), said Alexandre Shvartsburg, Ph.D., whose lab at the Pacific Northwest National Lab, has achieved the highest resolution to date (~330 peptides) using planar FAIMS.

    While not exactly new, FAIMS has undergone steady refinement with at least one commercial FAIMS product on the market and several more announced, added Dr. Shvartsburg. Broadly, FAIMS is a gas-phase, ion-separation, interface technology that permits researchers to more effectively separate ions and select which of those ions are passed to the MS for analysis.

    Dr. Shvartsburg noted that, “FAIMS is not a single thing. It’s a technology. We are working on really pushing the frontier of resolution at the expense of sensitivity, unfortunately as always. Others use it differently.

    “For localization of post-translational modifications, FAIMS pretty much beats any other method, and I think this is going to be a major application. So far we’ve tried it for phosphorylation and acetylation, but there is really no reason (e.g., special chemistries) it should apply only to those two.”

  • Tunable Process

    In FAIMS, the asymmetric waveform combines a high-strength dispersive voltage (DV), which moves ions toward one or the other electrodes, with a lower strength compensation voltage (CV) used to trap select ions in the sample and send them into the MS. An inert gas is used to shorten the time required for ions to reach terminal velocity.

    The entire process is tunable (varying the CV, DV, gas concentration) so researchers can change which ions are trapped and sent to the MS. (For a complete explanation, see www.FAIMS.com.) The net result is better noise reduction, greater ion separation, and higher resolution.

    FAIMS systems have varying attributes, some suited for proteomics (larger molecules) and others for metabolomics (smaller molecules). One publicly announced effort (Agilent Technologies and Owlstone) “is very unique,” said Dr. Shvartsburg. “It’s a microchip FAIMS that is almost invisible and sits within the inlet capillary to the mass spec and is smaller than the size of the fingernail. I have worked with them. They don’t have the kind of resolution we have, but they do have much better sensitivity and the speed is amazing at 10 ms analysis.”

    Dr. Shvartsburg, who has published widely on FAIMS, said the technology might find use in histone code analysis, “which some people will say is the most important area of PTMs.” He expects FAIMS resolution to improve by two- to threefold over the next couple of years.

    One intriguing result is FAIMS ability to distinguish isotopomers. “It’s new but FAIMS can separate some isotopomers in the gas phase. It is stunning and so far not theoretically understood. We discovered it accidentally. It could be a fundamentally new approach for identification of molecular structure using the gas phase of the molecule. In a way like NMR it fingerprints molecules in solution but the resolution would have to get much better.”

  • Microbial Genome Mining

    Discovery of new antibiotics has slowed so much that “we could run out antibiotics to treat life-threatening infection very soon,” said senior researcher Lijiang Song, Ph.D., experimental officer in mass spectrometry at the University of Warwick. “This is why the American infectious disease society proposed that we need to discover 10 new antibiotics by 2020, which many people think is overambitious if not impossible. The main reason has been the high rate of re-discovery of known compounds.

    “We have addressed this problem by employing high-resolution mass spectrometry to do de-replication in the modern microbial genome mining approach for novel natural products. This means we can identify known compounds very early on and shift our focus to true novel compounds.

    “We have successfully identified and characterized more than 30 new compounds in the last five years and patented two families of novel bioactive microbial polyketide natural products (as antibiotics or anticancer agents.)”

    Dr. Song’s methodology was created “to analyze the genome sequence first to identify potential interesting secondary metabolite gene clusters, such as PKS, NRPS, where one can even predict whole or part of the structure of the secondary metabolite if made.

    “We then make knock-out mutants and carry out comparative metabolite profiling with LC-UV-MS/MS for wild-type and knock-out mutants to identify novel targets, followed by structure elucidation with MS and NMR.”

    Dr. Song labels HR-MS/MS as “probably the most efficient way to do de-replication while high-resolution and high-accurate MS is probably the most sensitive (nanogram or even lower) and reliable way to do de-replication.”

    With the emergence of high-speed, high-resolution MS, particularly the Bruker MaXis UHR-Q-TOF, said Dr. Song, it has become possible to screen a large number of samples for novel bioactive natural products by using UHPLC coupling with HR-MS/MS and still identify novel compounds quickly.

    Dr. Song predicts that this approach will find its way into most natural product-based drug discovery programs. “Apparently, the current 40–60,000 resolution is good enough for most of the things we analyze, but it is not enough to distinguish sulphur isotope, which is one of the element contained in many natural products.

    “I would like to think the resolution of Q-TOF HRMS will reach 100,000 in a few years time. By then HRMS/MS will become even more useful. Though many may argue that FT-ICR is better, the running cost for FT-ICR turned out to be too high for most of the labs. Their extreme high resolution (millions) is probably most suited for more specific applications.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?